Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Cancers
|
May 13, 2023
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, et al.
The Oncologist
|
September 19, 2025
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study
Deirdre J Cohen, Judith D Goldberg, Lawrence Leichman, et al.
Cancer Medicine
|
June 16, 2023
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
Weijing Sun, Nirmal Veeramachaneni, Raed Al-Rajabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2021
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181
Antoine Adenis, Amit S Kulkarni, Gustavo C Girotto, et al.
Cell Reports. Medicine
|
January 26, 2023
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
Anwaar Saeed, Robin Park, Junqiang Dai, et al.
Cells
|
September 28, 2023
Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
Ian M Freed, Anup Kasi, Oluwadamilola Fateru, et al.
Nature Communications
|
February 20, 2024
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh Pathak, et al.
Annals of Surgery
|
February 25, 2021
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Daniel Brock Hewitt, Nicholas Nissen, Hassan Hatoum, et al.
The Lancet. Oncology
|
March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Liver Cancer
|
March 27, 2025
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma
Ghassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Cancers
|
May 13, 2023
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, et al.
The Oncologist
|
September 19, 2025
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study
Deirdre J Cohen, Judith D Goldberg, Lawrence Leichman, et al.
Cancer Medicine
|
June 16, 2023
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
Weijing Sun, Nirmal Veeramachaneni, Raed Al-Rajabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2021
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181
Antoine Adenis, Amit S Kulkarni, Gustavo C Girotto, et al.
Cell Reports. Medicine
|
January 26, 2023
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
Anwaar Saeed, Robin Park, Junqiang Dai, et al.
Cells
|
September 28, 2023
Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
Ian M Freed, Anup Kasi, Oluwadamilola Fateru, et al.
Nature Communications
|
February 20, 2024
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh Pathak, et al.
Annals of Surgery
|
February 25, 2021
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Daniel Brock Hewitt, Nicholas Nissen, Hassan Hatoum, et al.
The Lancet. Oncology
|
March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Liver Cancer
|
March 27, 2025
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma
Ghassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, et al.
Page
of 3